Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

@article{Fernndez2016DifferencesIM,
  title={Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.},
  author={Marta Llaurad{\'o} Fern{\'a}ndez and Gabriel E Dimattia and Amy Dawson and Sylvia Bamford and Shawn A Anderson and Bryan T. J. Hennessy and Michael S Anglesio and Trevor G. Shepherd and Clara M. Salamanca and Josh Hoenisch and Anna V. Tinker and David G. Huntsman and Mark S. Carey},
  journal={American journal of cancer research},
  year={2016},
  volume={6 10},
  pages={2235-2251}
}
Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in RAS or RAF, leading to several clinical trials evaluating MEK inhibitors (MEKi). As LGSC cell lines and xenografts have been difficult to establish, little is known about the efficacy and on-target activity of MEKi treatment in this disease. We compared four different MEKi (trametinib, selumetinib, binimetinib and refametinib) in novel LGSC patient-derived… CONTINUE READING